Cargando…
Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient
Vedolizumab is a humanized monoclonal integrin blocker with gut selective effects on lymphocyte trafficking. Its efficacy and safety for the treatment of moderate to severe Crohn’s disease and ulcerative colitis were demonstrated by phase III GEMINI studies (GEMINI 1 trial: Vedolizumab as Induction...
Autores principales: | Groudan, Kevin, Gupta, Kamesh, Singhania, Rohit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797417/ https://www.ncbi.nlm.nih.gov/pubmed/33457145 http://dx.doi.org/10.7759/cureus.12582 |
Ejemplares similares
-
Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab
por: Yeh, Jennifer E., et al.
Publicado: (2017) -
Pyoderma Gangrenosum: An Ulcer With Unorthodox Treatment
por: Baruah, Tridip Dutta, et al.
Publicado: (2021) -
Recurrent Genital Herpes Triggering Ulcerative Pyoderma Gangrenosum
por: Deoghare, Shreya, et al.
Publicado: (2023) -
A Case of Recurrent Idiopathic Pyoderma Gangrenosum
por: David, Filipa, et al.
Publicado: (2022) -
Pyoderma Gangrenosum as a Presenting Feature of Takayasu Arteritis
por: Batool, Wajeeha, et al.
Publicado: (2023)